{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:39:17Z","timestamp":1782779957210,"version":"3.54.5"},"reference-count":96,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/14760584.2025.2505754","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:42:53Z","timestamp":1747111373000},"page":"416-432","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis"],"prefix":"10.1080","volume":"24","author":[{"given":"Kyle","family":"Fahrbach","sequence":"first","affiliation":[{"name":"Evidera Inc","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie","family":"Cichewicz","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Di Fusco","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, NY, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Volkman","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, NY, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morodoluwa","family":"Akin-Fajiye","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Fernando","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, NY, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"European Medicines Agency. COVID-19 medicines. [cited 2025 Mar 14]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines"},{"key":"e_1_3_7_4_1","unstructured":"US Food & Drug Administration. COVID-19 vaccines. [cited 2024 Sep 18]. Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines"},{"key":"e_1_3_7_5_1","unstructured":"World Health Organization. Potential benefits and limitations of mRNA technology for vaccine research and development for infectious diseases and virus-induced cancers. Report of the WHO science council. World Health Organization; 2023 [cited 2025 Mar 14]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/375031\/9789240084551-eng.pdf?sequence=1"},{"key":"e_1_3_7_6_1","unstructured":"FDA approves and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants [Internet]. US Food & Drug Administration; 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_3_7_9_1","unstructured":"European Medicines Agency. Comirnaty. [cited 2025 Mar 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/comirnaty"},{"key":"e_1_3_7_10_1","unstructured":"US Food & Drug Administration. Moderna COVID-19 vaccine. [cited 2025 Mar 14]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/coronavirus-covid-19-cber-regulated-biologics\/moderna-covid-19-vaccine"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017"},{"key":"e_1_3_7_13_1","unstructured":"European Medicines Agency. Health technology assessment body. [cited 2025 Mar 14]. Available from: https:\/\/www.ema.europa.eu\/en\/glossary-terms\/health-technology-assessment-body"},{"key":"e_1_3_7_14_1","unstructured":"Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5 [Internet]. European Medicines Agency; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-ema-recommends-approval-adapted-covid-19-vaccine-targeting-omicron-xbb15"},{"key":"e_1_3_7_15_1","unstructured":"Spikevax: EMA recommends approval of adapted COVID-19 vaccine targeting omicron XBB.1.5 [Internet]. European Medicines Agency; 2023 [cited 2025 Jan 22]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/spikevax-ema-recommends-approval-adapted-covid-19-vaccine-targeting-omicron-xbb15"},{"key":"e_1_3_7_16_1","unstructured":"Moderna receives U.S. FDA approval for updated COVID-19 vaccine [Internet]. Moderna. 2023 [cited 2025 Jan 22]. Available from: https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Receives-U.S.-FDA-Approval-for-Updated-COVID-19-Vaccine\/default.aspx"},{"key":"e_1_3_7_17_1","unstructured":"Pfizer and BioNTech receive U.S. FDA approval for 2023\u20132024 COVID-19 vaccine [Internet]. Pfizer; 2024 [cited 2025 Jan 22]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-receive-us-fda-approval-2023-2024-covid"},{"key":"e_1_3_7_18_1","unstructured":"European Medicines Agency. Spikevax (previously COVID-19 vaccine moderna). 2024 [cited 2025 Mar 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax-previously-covid-19-vaccine-moderna"},{"key":"e_1_3_7_19_1","unstructured":"FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants [Internet]. US Food & Drug Administration; 2023 [cited 2025 Jan 22]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating"},{"key":"e_1_3_7_20_1","unstructured":"US Food and Drug Administration. COVID-19 vaccine safety surveillance. 2025 [cited 2025 Apr 10]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/covid-19-vaccine-safety-surveillance#:~:text=January%2010%2C%202025.%20The%20Center%20for%20Biologics Centers%20for%20Disease%20Control%20and%20Prevention%20(CDC)%2C"},{"key":"e_1_3_7_21_1","unstructured":"World Health Organization. GACVS COVID-19 sub-committee. 2025 [cited 2025 Apr 10]. Available from: https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/covid-19-vaccines\/subcommittee"},{"key":"#cr-split#-e_1_3_7_22_1.1","unstructured":"U.S. Centers for Disease Control and Prevention. Vaccine effectiveness studies [updated 2024 July 12"},{"key":"#cr-split#-e_1_3_7_22_1.2","unstructured":"cited 2024 Oct 19]. Available from: https:\/\/www.cdc.gov\/covid\/php\/surveillance\/vaccine-effectiveness-studies.html"},{"key":"e_1_3_7_23_1","unstructured":"Center IVA. VIEW-hub: COVID vaccines (COVID) study explorer - effectiveness studies. 2025 [cited 2025 Apr 10]. Available from: https:\/\/view-hub.org\/vaccine\/covid\/effectiveness-studies"},{"key":"e_1_3_7_24_1","unstructured":"Control ECfDPa. COVID-19 vaccination. 2025 [cited 2025 Apr 10]. Available from: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/prevention-and-control\/vaccines"},{"key":"e_1_3_7_25_1","unstructured":"(MHRA) UMHpRA. Research and analysis: Coronavirus vaccine - summary of yellow card reporting. 2025 [cited 2025 Apr 10]. Available from: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting"},{"key":"e_1_3_7_26_1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidance for reporting real-world evidence. 2023 [cited 2025 Mar 14]. Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/RWE\/MG0020\/MG0020-RWE-Guidance-Report-Secured.pdf"},{"key":"e_1_3_7_27_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choices in methods for economic evaluation \u2013 HAS. 2020 [cited 2025 Mar 14]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf"},{"key":"e_1_3_7_28_1","unstructured":"Institute for Quality and Efficiency in Health Care. General methods. 2023 [cited 2025 Mar 14]. Available from: https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf"},{"key":"e_1_3_7_29_1","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2023 [cited 2025 Mar 14]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.12.010"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.03.020"},{"key":"e_1_3_7_33_1","unstructured":"World Health Organization. Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination. Interim guidance. Second addendum to evaluation of COVID-19 vaccine effectiveness: interim guidance. 2022 [cited 2024 Sep 18]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/363344\/WHO-2019-nCoV-vaccine-effectiveness-VE-evaluations-2022.1-eng.pdf?sequence=1"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0522"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_7_38_1","unstructured":"Dias S Sutton AJ Welton NJ et al. NICE DSU technical support document 3: heterogeneity: subgroups meta-regression bias and bias-adjustment. 2011."},{"key":"e_1_3_7_39_1","unstructured":"Dias S Welton NJ Sutton AJ et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011."},{"key":"e_1_3_7_40_1","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"Higgins JT","year":"2024","unstructured":"Higgins JT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.5. 2024 [cited 2025 Mar 14]. Available from: www.training.cochrane.org\/handbook"},{"key":"e_1_3_7_41_1","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. 2009 [cited 2025 Mar 14]. Available from: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf"},{"key":"e_1_3_7_42_1","unstructured":"Wells GA. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Canada: University of Ottawa; [cited 2023 Nov 17]. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-93"},{"key":"e_1_3_7_44_1","unstructured":"CoVariants. Overview of variants in countries. [2025 Mar]. Available from: https:\/\/covariants.org\/per-country"},{"key":"e_1_3_7_45_1","unstructured":"Centers for Disease Control and Prevention. COVID data tracker: variant proportions. [2025 Mar]. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.595"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0132"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8360"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta9260"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682"},{"key":"e_1_3_7_58_1","unstructured":"Sturtz S Ligges U Gelman A. R2OpenBUGS: a package for running OpenBUGS from R: comprehensive R archive network. 2019. Available from: https:\/\/cran.r-project.org\/web\/packages\/R2OpenBUGS\/"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1201\/b16018"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.074"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00746-6"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13292"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2428800"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.37.2300587"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293449"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae132"},{"key":"e_1_3_7_68_1","doi-asserted-by":"crossref","unstructured":"Shrestha NK Burke PC Nowacki AS et al. Effectiveness of the 2023\u20132024 formulation of the coronavirus disease 2019 mRNA vaccine against the JN.1 variant. medRxiv. 2024 [cited 2024 20].","DOI":"10.1101\/2024.04.27.24306378"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad209"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126375"},{"key":"e_1_3_7_71_1","doi-asserted-by":"crossref","unstructured":"Appaneal HJ Lopes VV Puzniak L et al. Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US veterans affairs healthcare system. medRxiv. 2024:2024.12.26.24319566.","DOI":"10.1101\/2024.12.26.24319566"},{"key":"e_1_3_7_72_1","doi-asserted-by":"crossref","unstructured":"Rudolph AE Khan FL Sun X et al. Receipt of BNT162b2 KP.2 vaccine and COVID-19 CVS MinuteClinic visits in US adults. medRxiv. 2025:2025.01.15.24319342.","DOI":"10.1101\/2025.01.15.24319342"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53842-w"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.067"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400109"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae695"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v12i8.5740"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102995"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.2294"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49944"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.1640"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae370"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300703"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01091-1"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13839"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2021-111901"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069989"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040341"},{"key":"e_1_3_7_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01707-1"},{"key":"e_1_3_7_90_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260733"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-022-00429-1"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002567"},{"key":"e_1_3_7_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02321-z"},{"key":"e_1_3_7_94_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2208216"},{"key":"e_1_3_7_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12492"},{"key":"e_1_3_7_96_1","doi-asserted-by":"publisher","DOI":"10.25259\/IJMR_750_2024"},{"key":"e_1_3_7_97_1","unstructured":"European Medicines Agency. EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024\u20132025. 2024 [cited 2025 Jan 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/ema-confirms-its-recommendation-update-antigenic-composition-authorised-covid-19-vaccines-2024-2025_en.pdf"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2025.2505754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:46:52Z","timestamp":1765522012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2025.2505754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/14760584.2025.2505754"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2025.2505754","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}